UNSTRUCTURED
Advanced cutaneous melanoma has always been a dreaded diagnosis, but with the introduction of a number of practice-changing agents, namely targeted therapy and immunotherapy, considerable strides have been achieved in terms of survival rates. However, the introduction of these agents was associated with a variety of dermatological adverse event, some of which have shown a detrimental effect on the continuity of treatment. This holds especially true in the light of the current fragmentation of care provided by the managing health care professionals. This article sheds light on the impact of the scarcity of dermatology specialist input in the management of dermatological adverse events associated with advanced melanoma treatment. Furthermore, it looks into the potential avenues where dermatological input can bridge the gap in the care provided by oncologists, hence standardising the care provided to melanoma patients with dermatological adverse events.